SERATIOPEPTIDASE 10MG & DICLOFENAC 50MG
Diclofenac exerts potent anti-inflammatory, anti-pyretic and analgesic activity by inhibition of cyclo-oxygenase pathway (COX) and thus inhibits biosynthesis of prostaglandin and other pro-inflammatory mediators of pain pathway.
Serratiopeptidase, a bacterial peptide-cleaving enzyme obtained from Serratia marcescens. Serratiopeptidase is also a potent anti-inflammatory agent that exerts fibrinolytic and anti-edematic property. The therapeutic enzyme reduce inflammation and swelling in the affected area.
Diclofenac sodium + Serratiopeptidase is rapidly absorbed in the GIT. However, the absorption rate is very slow in enteric-coated formulations.
The drug can enter breast milk and synovial fluid after distribution. The plasma protein binding capability of Diclofenac sodium + Serratiopeptidase is about 99%.
Diclofenac sodium + Serratiopeptidase is extensively metabolized in the liver and converted into active metabolites.
The drug is extensively excreted in urine as glucuronide and sulfate conjugates. The rest of the elimination is via the bile. The terminal half-life of Diclofenac sodium + Serratiopeptidase is about 1-2 hours.